Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ipilimumab Data Impress, But Vaccine Control Could Complicate Review

Executive Summary

CHICAGO - The Phase III results for Bristol-Myers Squibb's ipilimumab represent a breakthrough in melanoma, stole the show at the 2010 American Society of Clinical Oncology annual meeting and are generally expected to presage the first approval of a CTLA-4 inhibitor and the first approval in the disease for more than a decade. But the unexpectedly lackluster performance of an experimental vaccine used with the trial drug and as a control has created some interesting clinical and regulatory plot twists

You may also be interested in...



Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize

Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.

Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize

Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.

Advisory Committee Review Will Test Whether One Trial Will Do The Trick For Bristol's Ipilimumab

Panelists may want to wait for results from a second Phase III trial and, given severe side effects, are likely to want a robust risk management plan.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel